Catalent to provide AstraZeneca with finishing and packaging for University of Oxford COVID-19 vaccine candidate
Late-stage manufacturing services will be conducted at Catalent’s facility in Anagni, Italy in preparation for large-scale commercial supply of the vaccine
CDMO Catalent has signed a deal with AstraZeneca to provide vial filling and packaging of the Anglo-Swedish pharmaceutical firm’s COVID-19 vaccine candidate being developed in conjunction with the University of Oxford, the US-based contract development and manufacturing organisation said Monday.
The late-stage manufacturing services will be conducted at Catalent’s facility in Anagni, Italy in preparation for large-scale commercial supply of the adenovirus vector-based COVID-19 vaccine candidate, AZD1222.
Catalent will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of the vaccine candidate from August 2020, and potentially through to March 2022 dependent on regulatory approval.
Catalent said Agnani offers capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes as well as primary and secondary packaging, including serialization, to support product launches for oral solids, sterile, and biologics products.
Alessandro Maselli, President and Chief Operating Officer at Catalent said the 28,000 square-meter Anagni site has often been used as a primary launch facility for new medicines.
“Catalent has significant experience in the tech transfer and rapid scale-up of vaccine programs to meet demand,” he added.
Catalent’s Biologics network includes sterile drug product manufacturing and packaging facilities in Brussels, Belgium and Bloomington, Indiana, and additional facilities in Europe and the US for manufacturing proteins, viral vectors for gene therapies and cell therapies, and biologics analytical services.
The recombinant adenovirus vaccine technology was created by the Jenner Institute at the University of Oxford, and AZD1222 is currently in clinical trials.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance